Trial Review

Did you know?

The ANZCTR now automatically displays published trial results and simplifies the addition of trial documents such as unpublished protocols and statistical analysis plans.

These enhancements will offer a more comprehensive view of trials, regardless of whether their results are positive, negative, or inconclusive.

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been endorsed by the ANZCTR. Before participating in a study, talk to your health care provider and refer to this information for consumers
Trial details imported from ClinicalTrials.gov

For full trial details, please see the original record at https://clinicaltrials.gov/study/NCT00134693




Registration number
NCT00134693
Ethics application status
Date submitted
24/08/2005
Date registered
25/08/2005
Date last updated
31/07/2017

Titles & IDs
Public title
A Single Dose Of Compound SB-681323 Compared To Prednisolone On A Protein That Is an Indicator For Rheumatoid Arthritis
Scientific title
A Randomised, Placebo-controlled, Parallel Group Single Dose Study of SB681323 in Patients With Active RA to Investigate the CRP Dose Response Relationship
Secondary ID [1] 0 0
RA1104046
Universal Trial Number (UTN)
Trial acronym
Linked study record

Health condition
Health condition(s) or problem(s) studied:
Arthritis, Rheumatoid 0 0
Condition category
Condition code
Musculoskeletal 0 0 0 0
Osteoarthritis
Inflammatory and Immune System 0 0 0 0
Rheumatoid arthritis

Intervention/exposure
Study type
Interventional
Description of intervention(s) / exposure
Comparator / control treatment
Control group

Outcomes
Primary outcome [1] 0 0
Analysis for C-Reactive protein (CRP) levels 72 hours post-dose following SB-681323
Timepoint [1] 0 0
Day 3 (at 72 hour)
Secondary outcome [1] 0 0
Analysis of CRP levels 24 and 48 hours post-dose following SB-681323
Timepoint [1] 0 0
Day 1 (at 24 hour) and Day 2 (at 48 hour)
Secondary outcome [2] 0 0
Analysis of Interleukin (IL)-6 levels up to 72 hours post-dose following SB-681323
Timepoint [2] 0 0
Upto Day 3 (at 1, 3, 24 and 72 hour)
Secondary outcome [3] 0 0
Number of participants with adverse events (AE) and serious adverse events (SAE)
Timepoint [3] 0 0
Upto Day 3 (72 hours)
Secondary outcome [4] 0 0
Change from Baseline in vital sign systolic blood pressure (SBP) and diastolic blood pressure (DBP)
Timepoint [4] 0 0
Baseline (at pre-dose Day 0) and Day 3 (at 90 minutes, 3 hour, 24 and 72 hour)
Secondary outcome [5] 0 0
Change from Baseline in vital sign heart rate
Timepoint [5] 0 0
Baseline (at pre-dose Day 0) and Day 3 (at 90 minutes, 3 hour, 24 and 72 hour)
Secondary outcome [6] 0 0
Number of participants with abnormal electrocardiogram (ECG) findings
Timepoint [6] 0 0
Day 1 (pre-dose, 1 hour and 3 hour)
Secondary outcome [7] 0 0
Number of participants with clinical chemistry data outside the clinical concern range
Timepoint [7] 0 0
Upto Day 3 (pre-dose, 24, 48 and 72 hours
Secondary outcome [8] 0 0
Number of participants with hematology data outside the clinical concern
Timepoint [8] 0 0
Upto Day 3 (pre-dose, 24 and 72 hours)
Secondary outcome [9] 0 0
Number of participants with abnormal urinalysis dipstick results
Timepoint [9] 0 0
Upto Day 3 (pre-dose, 24 and 72 hours)
Secondary outcome [10] 0 0
Whole blood messenger RNA (mRNA) levels of tumor necrosis factor alpha [TNF-a], IL-8, IL-1ß and Cyclo-oxygenase-2 [COX-2] (and other genes implicated in the pathogenesis of RA or genes involved in the mode of action of the compounds administered)
Timepoint [10] 0 0
Pre-dose, 45 minutes, 90 minutes and 3 hours on Day 1

Eligibility
Key inclusion criteria
Inclusion criteria:

* Must have a diagnosis of RA according to the revised 1987 criteria of the American College of Rheumatology.
* Must have 3 or more swollen or 3 or more tender/painful joints at screening.
* Must be on stable weekly methotrexate (2.5mg - 25mg) for at least eight weeks prior to screening.
Minimum age
18 Years
Maximum age
No limit
Sex
Both males and females
Can healthy volunteers participate?
No
Key exclusion criteria
Exclusion criteria:

* Must not be morbidly obese.

Study design
Purpose of the study
Treatment
Allocation to intervention
Randomised controlled trial
Procedure for enrolling a subject and allocating the treatment (allocation concealment procedures)
Methods used to generate the sequence in which subjects will be randomised (sequence generation)
Masking / blinding
Blinded (masking used)
Who is / are masked / blinded?
The people receiving the treatment/s


The people analysing the results/data
Intervention assignment
Parallel
Other design features
Phase
Phase 2
Type of endpoint/s
Statistical methods / analysis

Recruitment
Recruitment status
Completed
Data analysis
Reason for early stopping/withdrawal
Other reasons
Date of first participant enrolment
Anticipated
Actual
21/06/2005
Date of last participant enrolment
Anticipated
Actual
Date of last data collection
Anticipated
Actual
3/08/2006
Sample size
Target
Accrual to date
Final
77
Recruitment in Australia
Recruitment state(s)
NSW,QLD,SA,TAS,WA
Recruitment hospital [1] 0 0
GSK Investigational Site - Darlinghurst
Recruitment hospital [2] 0 0
GSK Investigational Site - Douglas
Recruitment hospital [3] 0 0
GSK Investigational Site - Woolloongabba
Recruitment hospital [4] 0 0
GSK Investigational Site - Daw Park
Recruitment hospital [5] 0 0
GSK Investigational Site - Woodville
Recruitment hospital [6] 0 0
GSK Investigational Site - Hobart
Recruitment hospital [7] 0 0
GSK Investigational Site - Shenton Park
Recruitment postcode(s) [1] 0 0
2010 - Darlinghurst
Recruitment postcode(s) [2] 0 0
4814 - Douglas
Recruitment postcode(s) [3] 0 0
4102 - Woolloongabba
Recruitment postcode(s) [4] 0 0
5041 - Daw Park
Recruitment postcode(s) [5] 0 0
5011 - Woodville
Recruitment postcode(s) [6] 0 0
7000 - Hobart
Recruitment postcode(s) [7] 0 0
6008 - Shenton Park
Recruitment outside Australia
Country [1] 0 0
France
State/province [1] 0 0
Picardie
Country [2] 0 0
France
State/province [2] 0 0
Montpellier Cedex 5
Country [3] 0 0
Germany
State/province [3] 0 0
Baden-Wuerttemberg
Country [4] 0 0
Germany
State/province [4] 0 0
Niedersachsen
Country [5] 0 0
Germany
State/province [5] 0 0
Sachsen
Country [6] 0 0
Germany
State/province [6] 0 0
Berlin
Country [7] 0 0
Russian Federation
State/province [7] 0 0
Ekaterinburg
Country [8] 0 0
Russian Federation
State/province [8] 0 0
Moscow
Country [9] 0 0
Russian Federation
State/province [9] 0 0
Ryazan
Country [10] 0 0
Russian Federation
State/province [10] 0 0
Yaroslavl
Country [11] 0 0
United Kingdom
State/province [11] 0 0
Cambridgeshire
Country [12] 0 0
United Kingdom
State/province [12] 0 0
Lancashire
Country [13] 0 0
United Kingdom
State/province [13] 0 0
Merseyside
Country [14] 0 0
United Kingdom
State/province [14] 0 0
Northumberland
Country [15] 0 0
United Kingdom
State/province [15] 0 0
Oxford
Country [16] 0 0
United Kingdom
State/province [16] 0 0
Sheffield

Funding & Sponsors
Primary sponsor type
Commercial sector/industry
Name
GlaxoSmithKline
Address
Country

Ethics approval
Ethics application status

Summary
Brief summary
This study is designed to compare a range of doses of SB-681323 with prednisolone, which has known effects on rheumatoid arthritis patients. By comparing the two drugs and their effects on blood proteins that indicate for rheumatoid arthritis, we hope to ascertain information on the most effective dose of SB-681323 to use in future.
Trial website
https://clinicaltrials.gov/study/NCT00134693
Trial related presentations / publications
Public notes

Contacts
Principal investigator
Name 0 0
GSK Clinical Trials
Address 0 0
GlaxoSmithKline
Country 0 0
Phone 0 0
Fax 0 0
Email 0 0
Contact person for public queries
Name 0 0
Address 0 0
Country 0 0
Phone 0 0
Fax 0 0
Email 0 0
Contact person for scientific queries



Summary Results

For IPD and results data, please see https://clinicaltrials.gov/study/NCT00134693